The Annals Take our Readership Survey!
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 35, No. 9, pp. 1108-1113. DOI 10.1345/aph.10253
© 2001 Harvey Whitney Books Company.
This Article
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by El-Beyrouty, C
Right arrow Articles by Spinler, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by El-Beyrouty, C
Right arrow Articles by Spinler, S.

Research Articles

Cilostazol for prevention of thrombosis and restenosis after intracoronary stenting

C El-Beyrouty and SA Spinler

OBJECTIVE: To evaluate the potential use of cilostazol in intracoronary stenting. DATA SOURCES: Clinical literature was accessed through MEDLINE (1966-March 2001). Key search terms included cilostazol, intracoronary stenting, and coronary angioplasty. Abstracts of clinical trials presented at major cardiology professional association meetings were also reviewed. DATA SYNTHESIS: Intracoronary stent placement represents the fastest growing medical device implant. Complications of stent implantation include acute and subacute vessel closure, as well as late restenosis. Currently, antiplatelet agents are used for preventive therapy. Cilostazol is a vasodilating antiplatelet agent that reversibly inhibits platelet aggregation induced by many factors. In seven randomized trials comparing cilostazol with either aspirin or ticlopidine, cilostazol was found to be superior to aspirin and equivalent to ticlopidine in decreasing both cardiac events and rates of restenosis. In addition, cilostazol was found to be well tolerated, with no reports of adverse hematologic events. CONCLUSIONS: Although further comparative trials are required, cilostazol appears to be a safe and effective alternative to clopidogrel and glycoprotein IIb/IIIa receptor antagonists following intracoronary stent implantation.


This article has been cited by other articles:


Home page
 Mol. Pharmacol.Home page
W. Zhang, H. Ke, and R. W. Colman
Identification of Interaction Sites of Cyclic Nucleotide Phosphodiesterase Type 3A with Milrinone and Cilostazol Using Molecular Modeling and Site-Directed Mutagenesis
Mol. Pharmacol., September 1, 2002; 62(3): 514 - 520.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
H. A. Dunkerley, D. G. Tilley, D. Palmer, H. Liu, S. L. Jimmo, and D. H. Maurice
Reduced Phosphodiesterase 3 Activity and Phosphodiesterase 3A Level in Synthetic Vascular Smooth Muscle Cells: Implications for Use of Phosphodiesterase 3 Inhibitors in Cardiovascular Tissues
Mol. Pharmacol., May 1, 2002; 61(5): 1033 - 1040.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2001 by Harvey Whitney Books Company.